Tekmira Pharmaceuticals Corp. shares (NASDAQ:TKMR) fell $1.74, or 11.6 percent, to close at $13.28 after the Vancouver, British Columbia-based company said that an open-label, single-arm phase II study of TKM-Ebola-Guinea had reached a predefined statistical endpoint and enrollment had been closed.